Molecularly targeted therapy for osteosarcoma: Where do we go from here?

Molecularly Targeted Therapy for Childhood Cancer

Volumn , Issue , 2010, Pages 459-498

  Ricafort, Rosanna ^b   Gorlick, Richard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84869046531     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-69062-9_21     Document Type: Chapter

References (235)

1. Ahuja D, Sáenz-Robles MT, Pipas JM. 2005. SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. Oncogene. 24:7729-45.
2. Akatsu T, Murakami T, Nishikawa M, Ono K, Shinomiya N, Tsuda E, Mochizuki S, Yamaguchi K, Kinosaki M, Higashio K, Yamamoto M, Motoyoshi K, Nagata N. 1998. Osteoclastogenesis inhibitory factor suppresses osteoclast survival by interfering in the interaction of stromal cells with osteoclast. Biochem Biophys Res Commun 250:229-34.
3. Akatsuka T, Wada T, Kokai Y, Kawaguchi S, Isu K, Yamashiro K, et al. 2002. ErbB2 expression is correlated with increased survival of patients with osteosarcoma. Cancer 94:1397-404.
4. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, et al. 2004. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 31:53-90.
5. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, et al. 1999. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 5:2316-23.
6. Anderson PM, Pearson M. 2006. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep 8:310-5.
7. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, et al. 2002. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20:189-96.
8. Anderson PM, Wiseman GA, Erlandson L, Rodriguez V, et al. 2005. Gemcitabine radiosensitization after high-dose samarium for osteblastic osteosarcoma. Cin Cancer Res 11:6895-6900.
9. Anninga JK, van der Vijver MJ, Cleton-Jansen AM, Kristel PMP, Taminiau AHM, Nooij M, Egeler RM, Hogendoorn PCW. 2004. Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. Eur J Cancer 40:963-970.
10. Arndt CA, Crist WM. 1999. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 341:342-52.
11. Ashton JA, Farese JP, Milner RJ, Lee-Ambrose LM, van Gilder JM. 2005. Investigation of the effect of pamidronate disodium on the in vitro viability of osteosarcoma cells from dogs. Am J Vet Res 66:885-91.
12. Aue G, Muralidhar B, Schwartz HS, Butler MG. 1998. Telomerase activity in skeletal sarcomas. Ann Surg Oncol 5:627-634.
13. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, et al. 2000. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol 18:4016-27.
14. Bagatell R, Beliakoff J, David CL, Marron MT, Whitesell L. 2005. Hsp90 inhibitors deplete key antiapoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int J Cancer 113:179-88.
15. Bagatell R, Gore L, Egorin MJ, Ho R, Heller G, Boucher N, et al. 2007. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17- demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 13:1783-8.
16. Baldini N, Scotlandi K, Barbanti-Brodano G, et al. 1995. Expression of p-glycoprotein in highgrade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385.
17. Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li WW, et al. 1995. Molecular mechanisms of resistance to antifolates, a review. Acta Biochim Pol. 42:457-64.
18. Baselga J, Norton L, Albanell J, Young-Mee K, Medelsohn J. 1998. Recombinant humanized anti-HER-2 antibody (HERceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825-2831.
19. Baserga R, Peruzzi F, Reiss K. 2003. The IGF-1 receptor in cancer biology. Int J Cancer 107:873-877.
20. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K et al. 2003. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 36:7-16.
21. Bech-Otschir, Kraft R, Huan X, Henklein P, Kapelari B, Pollmann C, Dubiel W. 2001. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J 20:1630-1639.
22. Benassi MS, Molendini L, Gamberi G, Ragazzini P, Sollazzo MR, Merli M, et al. 1999. Alteration of pRb/p16/cdk4 regulation in human osteosarcoma. Int J Cancer. 84:489-93.
23. Benini S, Baldini N, Manara MC, Chano T, Serra M, Rizzi S, et al. 1999. Redundancy of autocrine loops in human osteosarcoma cells. Int J Cancer. 80:581-8.
24. Bertoni F, Present D, Bacchini P, Pignatti G, Picci P, Campanacci M. 1989. The Istituto Rizzoli experience with small cell osteosarcoma. Cancer 64:2591-9.
25. Betino JR. 1993. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 11:5-14.
26. Bjornsti MA, Houghton PJ. 2004. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-48.
27. Bleul CC, Fuhlbrigge RC, Cassnovas JM, Aiuti A, Springer TA. 1996. A highly efficacious lymphocyte cheomattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 184:1101-1109.
28. Bode AM, Dong Z. 2004. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793-805.
29. Boland GM, Perkins G, Hall DJ, Tuan RS. 2004. Wnt3a promotes proliferation and suppresses osteogenic differentiation of adult human mesenchymal stem cells. J Cell Biochem 93:1210-1230.
30. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC. 2008. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 50:254-258.
31. Bostedt KT, Schmid C, Ghirlanda-Keller C, Ollie R, Winterhalter KH, Zapf J. 2001. Insulin-like growth factor (IGF) I down-regulates type 1 IGF receptor (IGF 1R) and reduces the IGF I response in A549 non-small-cell lung cancer and Saos-2/B-10 osteoblastic osteosarcoma cells. Exp Cell Res 271:368-377.
32. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB. 2000. Abl protein-tyrosine kinase inhibitor ST1571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 295:139-145.
33. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, Lydon NB. 1995. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA. 92:2558-2562.
34. Burrow S, Andrulis IL, Pollak M, Bell RS. 1998. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69:21-7.
35. Carbone M, Rizzo P, Procopio A, Giuliano M, Pass HI, Gebhardt MC, Mangham C, Hansen M, Malkin DF, Bushart G, Pompetti F, Picci P, Levine AS, Bergsagel JD, Garcea RL. 1996. SV40-like sequences in human bone tumors. Oncogene 13:527-535.
36. Carli M, Passone E, Perilongo G, Bisogno G. 2003. Ifosfamide in pediatric solid tumors. Oncology 65 Suppl 2:99-104.
37. Carpio L, Gladu J, Goltzman D, Rabbani SA. 2001. Induction of osteoblast differentiation indexes by PTHrP in MG-63 cells involves multiple signaling pathways. Am J Phsyiol Endocrinol Metab. 281:E489-E499.
38. Carter JJ, Madeleine MM, Wipf GC, Garcea RL, Pipkin PA, Minor PD, Galloway DA. 2003. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst. 95:1522-30.
39. Casas-Ganem J, Healey JH. 2005. Advances that are changing the diagnosis and treatment of malignant bone tumors. Curr Opin Rheumatol. 17:79-85.
40. Chan HS, Grogan TM, Haddad G, DeBoer G, Ling V. 1997. P-glycoprotein expression: critical determinant in the response to osteosarcoma chemotherapy. J Natl Cancer Inst 89:1706-1715.
41. Charity RM, Foukas AF, Deshmukh NS, Grimer RJ. 2006. Vascular endothelial growth factor expression in osteosarcoma. Clin Orthop Relat Res 448:193-8.
42. Cheng YY, Huang L, Lee KM, Li K, Kumta SM. 2004. Alendronate regulates cell invasion and MMP-2 secretion in human osteosarcoma cell lines. Pediatr Blood Cancer. 42:410-5.
43. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, et al. 2000. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs. 18:253-9.
44. Chou A, Merola P, Sowers R, Yang R, Kolb E, Healey J, et al. 2005a. Analysis of Aberrant signal transduction pathways in osteosarcoma cell lines. Proc Am Assoc Cancer Res 46: Abstract #4551, 1075.
45. Chou AJ, Merola PR, Wexler LH, Gorlick RG, Vyas YM, Healey JH, et al. 2005b. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104:2214-21.
46. Chou AJ, Bell MD, Mackinson C, Gupta R, Meyers PA, Gorlick R. 2007. Phase Ib/IIa study of sustained release lipid inhalation targeting cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung. J Clin Oncol ASCO Annual Meeting Proceedings Part I. 25:18S; Abstract #9525.
47. Chou AJ, Gorlick R. 2006. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 6:1075-85.
48. Classon M, Harlow E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2:910-7.
49. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE, Tengowski MW, Wang F, Gualberto A, Beebe JS, Moyer JD. 2005. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11:2063-2073.
50. Corcione A, Ottonello L, Tortolina G, Facchetti P, Airoldi I, Guglielmino R, Dadati P, Truini M, Sozzani S, Dallegri F, Pistoia V. 2000. Stomal cell-derived factor-1 as a chemoattractant for follicular center lymphoma B cells. J Natl Cancer Inst 92:628-635.
51. Cowley S, Paterson H, Kemp P, Marshall CJ. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell. 77:841-52
52. Curran T, MacConnell WP, van Straaten F, Verma IM. 1983. Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol Cell Biol. 3:914-21
53. David JP, Mehic D, Bakiri L, Schilling AF, Mandic V, Priemel M, et al. 2005. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 115:664-72.
54. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, et al. 2002. Mutations of the BRAF gene in human cancer. Nature. 417:949-54.
55. Davis AM, Bell RS, Goodwin PJ. 1994. Prognostic factors in osteosarcoma: a critical review. J Clin Oncol. 12:423-31.
56. DeLaney TF, Park L, Goldberg SI, Hug EB, Liebsch NJ, Munzenrider JE, et al. 2005a. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 61:492-8.
57. DeLaney TF, Trofimov AV, Engelsman M, Suit HD. 2005b. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control 12:27-35.
58. Diel IJ, Solomayer EF, Bastert G. 2000. Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88:3080-3088.
59. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-21.
60. Draper GJ, Sanders BM, Kingston JE. 1986. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 53:661-671.
61. Druker BJ, Tamura S, Buchdunger E, Ohno S, et al. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
62. DuBois S, Demetri G. 2007. Markers of angiogenesis and clinical features in patients with sarcoma. Cancer. 109:813-9.
63. Easton JB, Houghton PJ. 2006. mTOR and cancer therapy. Oncogene 25:6436-46.
64. El-Diery WS. 1998. Regulation of p53 downstream genes. Sem Cancer Biol 8:345-57.
65. Ellis NA, Groden J, Ye TZ, Straughen J, Lennon DJ, Ciocci S, et al. 1995. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 83:655-666.
66. Erfle V, Schmidt J, Strauss GP, Hehlmann R, Luz A. 1986. Activation and biological properties of endogenous retroviruses in radiation osteosarcomagenesis. Leuk Res 10:905-13.
67. Ferracini R, Renzo MFD, Scotlandi K, et al. 1995. The Met/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or autocrine circuit. Oncogene 10:739-49.
68. Feugas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon P, Babin S et al. 1996. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14:467-472.
69. Finkel MP, Biskis BO, Jinkins PB. 1966. Virus induction of osteosarcomas in mice. Science 151:698-701.
70. Franchi A, Calzolari A, Zampi G. 1998. Immunohistochemical detection of c-fos and c-jun expression in osseous and cartilaginous tumours of the skeleton. Virchows Arch 432:515-519.
71. Fukaya Y, Ishiguro N, Senga T, Ichigotani Y, Sohara Y, Tsutsui M, Shioura T, Iwamoto T, Hamaguchi M. 2005. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncol Rep.14:847-52.
72. Gamberi G, Benassi MS, Bohling T, Ragazzini P, Molendini L, Solazzo MR, et al. 1998. C-myc and c-fos in human osteosarcoma: prognostic value of mRNA and protein expression. Oncology 55:556-563.
73. Gelberg KH, Fitzgerald EF, Hwang S, Dubrow R. 1997. Growth and development and other risk factors for osteosarcoma in children and young adults Int J Epidemiol. 26:272-278.
74. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW, et al. 2005. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia. 7:967-76.
75. Goetsch L, Gonzalez A, Leger O, et al. 2005. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113:316-328
76. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. 1996. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 11:5-14.
77. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, et al. 1999. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol. 17:2781-8.
78. Gorlick R, Meyers PA. 2003a. Osteosarcoma necrosis following chemotherapy: innate biology versus treatment-specific. J Pediatr Hematol Oncol 25:840-1.
79. Gorlick R, Anderson P, Andrulis I, Arndt C, et al. 2003b. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res. 9:5442-5453.
80. Goto M, Miller RW, Ishikawa Y, Sugano H. 1996. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5:239-246.
81. Grigoriadis AE, Schellander K, Wang ZW, Wagner ER. 1993. Osteoblasts are target cells for transformation in c-fos transgenic mice. J Cell Biol 122:685-701.
82. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, et al. 1999. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res. 5:621-627.
83. Gupta SK, Lysko PG, Pillarisetti K, Ohlstein E, Stadel JM. 1998. Chemokine receptor in human endothelial cells. Functional expression of CXCR4 and its transctiptional regulation by inflammatory cytokines. J Biol Chem. 273:4282-4287.
84. Hailey J, Maxwell E, Koukouras K, Bishop WR, Patcher JA, Wang Y. 2002. Neutralizing antiinsulin-like growth factor receptor 1 antibodies inhibit receptor function and induce receptor degradation in tumor cells. Mol Cancer Ther. 1:1349-1353.
85. Haluska P, Carboni JM, Loegering DA, Lee FY, Wittman M, Saulnier MG, et al. 2006. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res. 66:362-371.
86. Hanahan D and Weinberg RA. 2000. The hallmarks of cancer. Cell 100:57-70.
87. Hancock MC, Langton BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. 1991. A monoclonal antibody against the c-erbB-2 signaling enhances the cytotoxity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 51:4575-4580.
88. Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad O, Brogger A, et al. 1985. Osteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predisposition. Proc Natl Acad Sci 82:6216-6220.
89. Haydon RX, Deyrup A, Ishikawa A, Heck R, et al. 2002a. Cytoplasmic and/or nuclear accumulation of the b-catenin protein is a frequent event in human osteosarcoma. Int J Cancer 102:338-342.
90. Haydon RC, Zhou L, Feng T, Breyer B, Cheng H, Jian W, et al. 2002b. Nuclear receptor agonists as potential differentiation therapy agents for human osteosarcoma. Clin Cancer Res 8:1288-1294.
91. Haydon RC, Luu HH, He TC. 2007. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 454:237-246.
92. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, and Oberg K. 1993. Expression and prognostic significance of platelet-derived growth factor and its receoptors in epithelial ovarian neoplasms. Cancer Res. 53:4550-4554.
93. Henriksen J, Aagesen TH, Maelsandsmo GM, Lothe RA, Myklebost O, Forus A. 2003. Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 22:5358-5361.
94. Hoang BH, Kubo T, Healey JH, Sowers R, Mazza BA, Yang R, Huvos AG, Meyers PA, Gorlick R. 2004a. Expression of LDL receptor-related protein (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 109:106-111.
95. Hoang BH, Kubo T, Healey JH, Yang R, Nathan SS, Kolb EA, Mazza BA, Meyers PA, Gorlick R. 2004b. Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-b-catenin pathway. Cancer Res. 64:2734-2739.
96. Hornicek FJ, Gebhardt MC, Wolfe MW, Kharrazi FD, Takashita H, Parekh SG, et al. 2000. P-glycoprotein levels predict poor outcome in patients with osteosarcoma. Clin Orthop Relat Res. 373:11-17.
97. Houghton PJ, Maris JM, Friedman HS, Keir ST, Lock RB, Carol H, et al. 2007a. Pediatric Preclinical Testing Program (PPTP) evaluation of the multi-targeted kinase inhibitor Sunitinib. In: American Association for Cancer Research Annual Meeting: Proceedings. Abstract #527.
98. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. 2007b. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 50(4):799-805.
99. Houghton PJ, Morton CL, Kolb EA, Lock R, Carol H, Reynolds CP, et al. 2008. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer 50:37-45.
100. Hudis C. 2007. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51.
101. Hughes DP, Thomas DG, Giordano TJ, Baker LH, McDonagh KT. 2004. Cell surface expression of epidermal growth factor receptor and her-2 with nuclear expression of her-4 in primary osteosarcoma. Cancer Res. 64:2047-2053.
102. Hughes DP, Thomas DG, Giordano TJ, McDonagh KT, Baker LH. 2006. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer 46:614-23.
103. Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Takechi H, et al. 1989. Amplification of both c-myc and c-raf oncogenes in a human osteosarcoma. Jpn J Cancer Res 80:6-9.
104. Itoh Y, Tamai M, Yokogawa K, Nomura M, Moritani S, Suzuki H, et al. 2002. Involvement of multidrug resistance-associated protein 2 in in vivo cisplatin resistance of rat hepatoma AH66 cells. Anticancer Res 22:1649-53.
105. Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K. 2003. Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 20:525-529.
106. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA. 1994. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 4:1-7.
107. Jain M, Arvanitis C, Chu K, Dewey W, Leonhardt E, Trinh M, Sundberg CD, Bishop JM, Felsher DW. 2002. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:102-4.
108. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, et al. 2001. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-7.
109. Jung ST, Moon ES, Seo HY, Kim JS, Kim GJ, Kim YK. 2005. Expression and significance of TGF-beta isoform and VEGF in osteosarcoma. Orthopedics 28:755-760.
110. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C et al. 2005. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438:820-827.
111. Kappel CC, Velez-Yanguas MC, Hirschfeld S, and Helman LJ. 1994. Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res 54:2803-2807.
112. Kawai T, Hiroi S, Torikata C. 1997. Expression in lung carcinomas of platelet-derived growth factor and its receptors. Lab Invest 77:431-436.
113. Kaya M, Wada T, Akatsuka T, Kawaguchi S, Nagoya S, Shindoh M, et al. 2000. Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6:572-7.
114. Kaya M, Wada T, Kawaguchi S, Nagoya S, Yamashita T, Abe Y, et al. 2002. Increased pre-therapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer 6:864-9.
115. Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, et al. 2005. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23:559-68.
116. Khanna C, Prehn J, Yeung C, Caylor J, Tsokos M, Helman L. 2000. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin Exp Metastasis 18:261-271.
117. Khanna C, Khan J, Nguyen P, Prehn J, Caylor J, Yeung C, et al. 2001. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 61:3750-3759.
118. Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, et al. 2002. A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res 8:2406-12.
119. Khanna C, Wan X, Bose S, et al. 2004. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10:182-186.
120. Khidr L, Chen PL. 2006. RB, the conductor that orchestrates life, death and differentiation. Oncogene 25:5210-5219.
121. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, Bos GD. 2001. Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol 14:1277-1283.
122. Kleinerman ES. 1995. Biologic therapy for osteosarcoma using liposome-encapsulated muramyl tripeptide. Hematol Oncol Clin North Am 9:927-38.
123. Kloen P, Gebhardt MC, Perez-Atayde A, Rosenberg AE, Springfield DS, Gold LI, Makin HJ. 1997. Expression of transforming growth factor-beta isoforms in osteosarcomas: TGF-b3 is related to disease progression. Cancer 80:2230-2239.
124. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Billups CA, Smith MA. 2008. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1190-1197.
125. Knowles BB, McCarrick J, Fox N, Solter D, Damjanov I. 1990. Osteosarcomas in transgenic mice expressing an alpha-amylase-SV40 T-antigen hybrid gene. Am J Pathol.137:259-62.
126. Kochevar DT, Kochevar J, Garrett L. 1990. Low level amplification of c-sis and c-myc in a spontaneous osteosarcoma model. Cancer Lett. 53:213-22.
127. Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C, Helman LJ. 2006. Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 23:227-36.
128. Kubbutat MH, Jones SN, Vousden KH. 1997. Regulation of p53 stability by MDM2. Nature 387:299-303.
129. Kubo T, Gorlick R, Meyers P, Sowers R, et al. 2002. Expression and potential role of plateletderived growth factor receptor and c-Kit in relation to the antiproliferative effect of ST1571 in osteosarcoma. Proc Am Assoc Cancer Res 43:846.
130. Kulkarni NH, Halladay DL, Miles RR, Gilbert LM, Frolik CA, Galvin RJS, Martin RJ, Gillespie MT, Onyia JE. 2005. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 95:1178-1190.
131. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH. 1993a. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53:16-8.
132. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG. 1993b. Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2:63-167.
133. Laverdiere C, Kolb EA, Supko JG, Gorlick R, Meyers PA, Maki RG, et al. 2003. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer 98:832-40.
134. Laverdiere C, Hoang BH, Yang R, Sowers R, Qin J, Meyers PA, Huvos AG, Healey JH, Gorlick R. 2005. Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res. 11:2561-7.
135. Lawrence TS, Eishbruch A, McGinn CJ, Fields MT, Shewach DS. 1999. Radiosensitization by gemcitabine. Oncology 13:55-60.
136. Lee J, Hoang B, Chou A, Meyers P, Healey J, Gorlick R. 2007. Expression of vascular endothelial growth factor correlates with chemotherapy response in osteosarcoma patients. Am Assoc Cancer Res Annu Meet: Proc. #3489. 48:830.
137. Lee N, Smolarz AJ, Olson S, David O, Reiser J, Kutner R, et al. 2007. A potential role for Dkk-1 in the pathogenesis of osteosarcoma predicts novel diagnostic and treatment strategies. Br J Cancer 97:1552-1559.
138. Lee YH, Tokunaga T, Oshika Y, Suto R, Yanagisawa K, Tomisawa M, et al. 1999. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer 35:1089-93.
139. Li FP, Fraumeni JF Jr, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, Miller RW. 1988. A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358-5362.
140. Libura J, Drukala J, Majka M, Dreyfus MG, Tucker MA, Miller RW. 2002. CXCR4-SDF-1 signalingis active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood 100:2597-2606.
141. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, El-Naggar AK, Lozano G. 2000. High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci USA. 97:4174-9.
142. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. 2008. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50(6):1181-9.
143. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M. 1997. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 79:1541-47.
144. MacEwen EG, Kurzman ID, Rosenthal RC, Smith BW, Manley PA, Roush JK, Howard PE. 1989. Therapy of osteosarcoma in dogs with intravenous injection of liposome encapsulated muramyl tripeptide. J Natl Cancer Inst 81:935-936.
145. MacEwen EG, Pastor J, Kutzke J, Tsan R, Kurzman ID, Thamm DH, et al. 2004. IGF-1 receptor contributes to the malignant phenotype in human and canine osteosarcoma. J Cell Biochem 92:77-91.
146. Maitra A, Wanzer D, Weinber AG, Ashfaq R. 2001. Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. Cancer 92:677-83.
147. Malkin D, Li FP, Strong LC, Fraumeni JF, Jr, Nelson CE, Kim DH, et al. 1990. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
148. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S, Ladanyi M, Gorlick R, Lau CC, Rao PH. 2004. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer. 4:45.
149. Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, et al. 2002. Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol. 24:440-6.
150. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, Ahn NG. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase 1994. Science 265(5174):966-70.
151. Maris JM, Courtright J, Houghton PJ, Morton CL, Gorlick R, Kolb EA, et al. 2008. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50(3):581-7.
152. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, et al. 2002. Inhibition of plateletderived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 8:3584-91.
153. McIntyre JF, Smith-Sorensen B, Friend SH, Kassel, J, et al. 1994. Germline mutations of the p53 tumor suppressor gene in children with osteosarcoma. J Clin Oncol. 12:925-30.
154. Mendoza S, Konishi T, Miller CW. 1998. Integration of SV40 in human osteosarcoma DNA. Oncogene 17:2457-2462.
155. Meyers PA, Gorlick R. 1997. Osteosarcoma. Pediatr Clin North Am 44:973-89.
156. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. 2005. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004-11.
157. Miller AD, Curran T, Verma IM. 1984. c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell 36:51-60.
158. Miyamoto N, Higuchi Y, Mori K, Ito M, Tsurudome M, Nishio M, et al. 2002. Human osteosarcoma-derived cell lines produce soluble factor(s) that induces differentiation of blood monocytes to osteoclast-like cells. Int Immunopharmacol. 2:25-38.
159. Muggia FM. 2001. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 3:156-62.
160. Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. 1990. Mechanisms of p53 loss in human sarcomas. Proc Natl Acad Sci USA 87:5863-7.
161. Nellissery MJ, Padalecki SS, Brkanac Z, Singer FR, Roodman GD, Unni KK, Leach RJ, Hansen MF. 1998. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone. Am J Hum Genet. 63:817-24.
162. Nevins JR. 1992. E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258:424-429.
163. Nielsen GP, Burns KL, Rosenberg AE, Louis DN. 1998. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations. Am J Pathol 153(1):159-63.
164. Nishijo K, Nakayama T, Aoyama T, Okamoto T, Ishibe T, Yasura K, Shima Y, Shibata KR, Tsuboyama T, Nakamura T, Toguchida J. 2004. Mutation analysis of the RECQL4 gene in sporadic osteosarcomas. Int J Cancer 111:367-372.
165. Oda Y, Naka T, Takeshita M, Iwamoto Y, Tsuneyoshi M. 2000. Comparison of
166. Ohta S, Hiraki Y, Shigeno C, Suzuki F, Kasai R, Ikeda T, Kohno H, Lee K, Kikuchi H, Konishi J, et al. 1992. Bone morphogenetic proteins (BMP-2 and BMP-3) induce the late phase expression of the proto-oncogene c-fos in murine osteoblastic MC3T3-E1 cells. FEBS Lett. 314:356-360.
167. O'Keefe RJ, Guise TA. 2003. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res 415(Suppl):S100-S104.
168. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. 1992. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80-3.
169. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B. 1993. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362:857-60.
170. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T. 2004. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119:847-60.
171. Onda M, Matsuda S, Higaki S, Iijima T, Fukushima J, Yokokura A, Kojima T, Horiuchi H, Kurokawa T, Yamamoto T. 1996. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma. Cancer 77:71-78.
172. Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. 2005. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 104:2522-9.
173. Pakos EE, Ioannidis JPA. 2003. The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma: A meta-analysis. Cancer 98:581-589.
174. Park YB, Kim HS, Oh JH, Lee SH. 2001. The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24:307-310.
175. Perissinotto E, Cavalloni G, Leone F, Fonsato V, Mitola S, Grignani G, Surrenti N, Sangiolo D, Bussolino F, Piacibello W, Aglietta M. 2005. Involvement of chemokine receptor 4/stromal cellderived factor 1 system during osteosarcoma tumor progression. Clin Cancer Res. 11:490-497.
176. Polakis P. 2000. Wnt signaling and cancer. Genes Dev. 14:1837-1851.
177. Pollak MN, Polychronakos C, Richard M. 1990. Insulinlike growth factor I: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82:301-5.
178. Pompetti F, Rizzo P, Simon RM, Freidlin B, Mew DJ, Pass HI, Picci P, Levine AS, Carbone M. 1996. Oncogene alterations in primary, recurrent, and metastatic human bone tumors. J Cell Biochem 63:37-50.
179. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. 1995. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83:993-1000.
180. Rong S, Jeffers M, Resau JH, Tsarfaty I, Oskarsson M, Vande Woude GF. 1993. Met expression and sarcoma tumorigenecity. Cancer Res. 53:5355-60.
181. Rosen G, Caparros B, Huvos AG, Kosloff C, Nirenberg A, Cacavio A, et al. 1982. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49:1221-30.
182. Ruther U, Komitowski D, Schubert FR, Wagner EF. 1989. C-fos expression induces bone tumors in transgenic mice. Oncogene 4:861-865.
183. Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. 2003. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res. 63:627-635.
184. Salasznyk RM, Klees RF, Hughlock MK, Plopper GE. 2004. ERK signaling pathways regulate the osteogenic differentiation of human mesenchymal stem cells on collagen I and vitronectin. Cell Commun Adhes 11:137-53.
185. Sanders RP, Drissi R, Billups CA, Daw NC, Valentine MB, Dome JS. 2004. Telomerase expression predicts unfavorable outcome in osteosarcoma. J Clin Oncol. 22: 3790-7.
186. Sangiorgi L, Gobbi GA, Lucarelli E, Sartorio SM, Mordenti M, Ghedini I, Maini V, Scrimieri F, Reggiani M, Bertoja AZ, Benassi MS, Picci P. 2001. Presence of telomerase activity in different musculoskeletal tumor hitotypes and correlation with aggressiveness. Int J Cancer 95:156-161.
187. Schwartz CL, Gorlick R, Teot LA, Grier HE, Krailo M, Meyers PA. 2000. A prospective study of p-glycoprotein (P-GP) expression in newly diagnosed non-metastatic osteosarcoma: An intergroup study of the Children's Cancer Group and the Pediatric Oncology Group. Proc Am Soc Clin Oncol. 19:587a.
188. Schwartz CL, Gorlick R, Teot L, Krailo M, Chen Z, Goorin A, Grier HE, Bernstein ML, Meyers P. 2007. Mulitple drug resistance in osteogenic sarcoma: INT0133 from the Children's Oncology Group. J Clin Oncol. 25:2057-2062.
189. Scotlandi K, Baldini N, Oliviero M, Di Renzo MF, Martano M, Serra M, Manara MC, Comoglio PM, Ferracini R. 1996. Expression of Met/Hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol 149:1209-19.
190. Scotlandi K, Manara MC, Hattinger CM, Benini S, Perdichizzi S, Pasello M, et al. 2004. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 41:1349-61.
191. Scotlandi K, Manara MC, Nicoletti G, Lollini PL, Lukas S, Benini S, et al. 2005. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res. 65:3868-76.
192. Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, and Andrulis IL. 1995. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res. 55:129-134.
193. Serra M, Scotlandi K, Reverter-Branchat G, Ferrari S, Manara MC, Benini S, Incaprera M, Bertoni F, Mercuri M, Briccoli A, Bacci G, Picci P. 2003. Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol. 21:536-542.
194. Siddiqui R, Onel K, Facio F, Nafa K, Diaz LR, Kauff N, Huang H, Robson M, Ellis N, Offit K. 2005. The TP53 mutational spectrum and frequency of CHEK2 1100delC in Li-Fraumeni-like kindreds. Fam Cancer 4:177-181.
195. Skubitz KM. 2003. Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest. 21:167-76.
196. Somers GR, Ho M, Zielenska M, Squire JA, Thorner PS. 2005. HER2 amplification and overexpression is not present in pediatric osteosarcoma: a tissue microarray study. Pediatr Dev Pathol. 8:525-32.
197. Stock C, Kager L, Fink FM, Gadner H, Ambros PF. 2000. Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 28:329-336.
198. Sulzbacher I, Traxler M, Mosberger I, Lang S, and Chott A. 2000. Platelet-derived growth factor-AA and-alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol. 13:632-637.
199. Sulzbacher I, Birner P, Trieb K, Muhlbauer M, Lang S, and Chott A. 2001. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol. 25:1520-1527.
200. Taichman RS, Cooper C, Keller ET, Penta KJ, Taichman NS, McCauley LK. 2002. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res. 62:1832-1837.
201. Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC, Houghton PJ. 2003. Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 3-kinase-Akt signaling pathways. Cancer Res. 63:364-74.
202. Thomas DG, Giordano TJ, Sanders D, Biermann JS, Baker L. 2002. Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res. 8:788-793.
203. Thomas JE, Venugopalan M, Galvin R, Wang Y, Bokoch GM, Vlahos CJ. 1997. Inhibition of MG-63 cell proliferation and PDGF-stimulated cellular processes by inhibitors of phosphatidylinositol 3-kinase. J Cell Biochem. 64:182-95.
204. Toguchida J, Ishizaki K, Sasaki MS, Ikenaga M, Sugimoto M, Kotoura Y et al. 1988. Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Caner Res. 48:3939-3943.
205. Tolar J, Nauta AJ, Osborn MJ, Panoskaltsis Mortari A, McElmurry RT, Bell S, et al. 2007. Sarcoma derived from cultured mesenchymal stem cells. Stem Cells. 25:371-9.
206. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH, Ladanyi M. 2004. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 41:155-62.
207. Ulaner GA, Huang HY, Otero J, Zhao Z, Ben-Porat L, Satagopan JM, Gorlick R, Meyers P, Healey JH, Huvos AG, Hoffman AR, Ladanyi M. 2003. Absence of telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 63:1759-1763.
208. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB. 2002. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312-21.
209. Van BC, van SF, Curran T, Muller R, Verma IM. 1983. Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell 32:1241-1255.
210. Van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJM. 2004. Overexpression through amplification of genes in chromosome region 17q11.2-p12 in high-grade osteosarcoma. Cancer Genet Cytogenet. 152:8-14.
211. Van Dartel M, Hulsebos TJM. 2004. Amplification and overexpression of genes in 17p11.2-p12 in osteosarcoma. Cancer Genet Cytogenet. 153:77-80.
212. Vilella-Bach M, Nuzzi P, Fang Y, Chen J. The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression. J Biol Chem. 1999 Feb 12;274(7):4266-72.
213. Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y et al. 1994. Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res. 54:3042-3048.
214. Wan X, Mendoza A, Khanna C, Helman LJ. 2005. Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res. 65:2406-11.
215. Wang LL, Levy ML, Lewis RA, Chintagumpala MM, Lev D, Rogers M, Plon SE. 2001. Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet. 102:11-17.
216. Wang LL, Gannavarapu A, Kozinetz CA, Levy ML, Lewis RA, Chintagumpala MM, Ruiz-Maldanado R, Contreras-Ruiz J, Cunniff C, Erickson RP, Lev D, Rogers M, Zackai EH, Plon SE. 2003. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 95:669-674.
217. Wang ZQ, Liang J, Schellander K, Wagner EF, Grigoriadis AE. 1995. c-fos-induced osteosarcoma formation in transgenic mice: cooperativity with c-jun and the role of endogenous c-fos. Cancer Res. 55:6244-51.
218. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, et al. 1999a. CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 80:199-204.
219. Wei G, Gorlick R, Ladanyi M, Meyers P, Huvos AG, Bertino JR, Healey JH. 1999b. Expression of bone morphogenetic proteins and receptors in sarcomas. Clin Orthop Relat Res. 365:175-183.
220. Weiner LM, Adams GP. 2000. New approaches to antibody therapy. Oncogene 19:6144-6151.
221. Weiss KR, Cooper GM, Jadlowiec JA, McGough RL, Huard J. 2006. VEGF and BMP expression in mouse osteosarcoma cells. Clin Orthop Relat Res. 450:111-177.
222. Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA, Eigenbrot C, Yee H, Steiner G, Greco MA. 2007. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Human Pathol 38:1184-91.
223. Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, et al. 2006. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells. Int J Oncol. 28:261-9.
224. Wong FL, Boice JD, Abramson DH, Tarone RE, Kleinerman RA, Stoval M, et al. 1997. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. JAMA 278:1262-1267.
225. Wu JX, Carpenter PM, Gresens C, Keh R, Niman H, Morris JW, Mercola D. 1990. The protooncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5:989-1000.
226. Wunder JS, Bell RS, Wold L, Adrulis IL. 1993. Expression of the multidrug resistance gene in osteosarcoma: a pilot study. J Othopaed Res 11:396-403.
227. Wunder JS, Bull SB, Aneliunas V, Lee PD, Davis AM, Beauchamp CP, Conrad EU, Grimer RJ, Healey JH, Rock MJ, Bell RS, Andrulis IL. 2000. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol 18:2685-2694.
228. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, et al. 2001. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone 28:104-7.
229. Yamamoto O, Wda T, Takahashi M, Yamawaki S, Ishii S. 2000. Prognostic value of P-glycoprotein expression in bone and soft-tissue sarcoma. Int J Clin Oncol. 5:164-170.
230. Yang R, Hoang BH, Kubo T, Kawano H, Chou A, Sowers R, et al. 2007a. Over-expression of parathyroid hormone type 1 receptor confers an aggressive phenotype in osteosarcoma. Int J Cancer 121(5):943-54.
231. Yang R, Sowers R, Mazza B, Healey JH, Huvos A, Grier H, et al. 2003. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples. Clin Cancer Res. 9:837-44.
232. Yang R, Kolb EA, Qin J, Chou A, Sowers R, Hoang B, et al. 2007b. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5- methyltetrahydrofolate. Clin Cancer Res. 13:2557-67.
233. Yoshikawa H, Takaoka K, Masuhara K, Ono K, Sakamoto Y. 1988. Prognostic significance of bone morphogenetic activity in osteosarcoma tissue. Cancer 61:569-573.
234. Yu W, Chen Z, Zhang J, Zhang L, Ke H, Huang L, Peng Y, Zhang X, Li S, Lahn BT, Xiang AP. 2008. Critical role of phosphoinositide 3-kinase cascade in adipogenesis of human mesenchymal stem cells. Mol Cell Biochem 310(1-2):11-8.
235. Zhou H, Randall RL, Brothman AR, Maxwell T, Coffin CM, Goldsby RE. 2003. Her-2/neu expression in osteosarcoma increases risk of lung metastasis and can be associated with gene amplification. J Pediatr Hematol Oncol. 25:27-32.